MARKET WIREReuters • 2h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why ICCM Stock dropped -2.13% Today — RQD Quant Desk Flash
$0.96 -2.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.95
IceCure Medical Ltd. (ICCM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $3.3M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.95 (-0.57%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-5.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICCM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY ICCM SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (33% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 18.1 (OVERSOLD (<32))
▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (22% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$1.10-3.6% Next Q
54
Q2 (-2Q)Grade C-$1.06-4.7% Next Q
51
Q3 (-1Q)Grade D$1.01-5% Next Q
49
CurrentGrade D$0.96-6.1% Hist 90D α
46
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ICCM Turnaround Squeeze
While ICCM currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.66) and Max Pain ($1.01) forces dealer call-delta covering toward $24.66.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICCM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ICCM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ICCM Stock dropped -2.13% Today — RQD Quant Desk Flash
IceCure Medical Ltd. (ICCM) dropped -2.13% to $0.96, trading at 2% of its 52-week range ($0.82 – $23.49). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.82 – $23.49) with RSI-14 at 18.1 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.96 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 36.3% gross margin and $0 annual free cash flow.
Live ICCM Headlines & Catalysts
MARKET WIRECNBC • 4h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 4h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 6h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 8h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 9h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICCM)
- ✓Walkthrough of ICCM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ICCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -88.81%🛡️ HOLDING TREND SUPPORT
2026-10-30O $0.94H $0.96L $0.82C $0.96VOL 50.2K
SUP: $0.55SMA50: $1.66SMA200: $7.93
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ICCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +2.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ICCM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ICCM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ICCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICCM)
Health Care Rank #464 of 1016
⚔️ CODX vs ICCM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ICCM vs. CODX, XAIR, AMIX, IVF)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, IceCure Medical Ltd. (ICCM) ranks #464 by composite RQD confidence (46/100, grade D) and #977 by equity capitalization ($3.3M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while ICCM leads on capital efficiency and profitability with -35.0% ROIC and 36.3% gross margin. ICCM currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ICCM
ACTIVE
IceCure Medical Ltd. | D | 46/100 | — | 36.3% | -35.0% | -2.13% | $3.3M | Benchmark Subject |
| CODX Co-Diagnostics Inc. | D- | 37/100 | — | 64.3% | -35.0% | -10.49% | $3.5M | /codx-vs-iccm → |
| XAIR Beyond Air Inc. | D- | 42/100 | 112.1x | 3.3% | -35.0% | -2.12% | $3.8M | /xair-vs-iccm → |
| AMIX Autonomix Medical Inc. | D- | 37/100 | — | — | -35.0% | -5.12% | $4.0M | /amix-vs-iccm → |
| IVF INVO Fertility Inc. | D- | 43/100 | — | 96.0% | -35.0% | -3.60% | $2.5M | /ivf-vs-iccm → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001584371In its most recent audited fiscal period (FY2025, filed 2025-12-31), IceCure Medical Ltd. (ICCM) reported GAAP revenue of $3.4M (+2.7% vs. FY2024 revenue of $3.3M , and +4.6% cumulative change since FY2023) , GAAP net income of -$15.1M, operating cash flow of -$14.6M, and free cash flow of -$14.6M (-15.6% YoY). On the balance sheet, ICCM closed FY2025 with $13.9M in total assets against $13.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.4M | -$15.1M | -$14.6M | -$14.6M | $13.9M | $13.0K |
| FY2024 (FY) | 2024-12-31 | $3.3M | -$15.3M | -$12.6M | -$12.6M | $12.6M | $161.0K |
| FY2023 (FY) | 2023-12-31 | $3.2M | -$14.7M | -$12.6M | -$12.6M | — | — |
3. ICCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ICCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, IceCure Medical Ltd. (NASDAQ: ICCM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.96 (-2.13% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ICCM ranks #464 in composite RQD confidence.
How does ICCM compare to CODX and XAIR in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), ICCM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 36.3%, and ROIC of -35.0%. By comparison, CODX (Co-Diagnostics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M) and XAIR (Beyond Air Inc.) posts a D- grade (42/100 RQD, P/E 112.1x, ROIC -35.0%, cap $3.8M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while ICCM leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ICCM?
Per ICCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001584371), IceCure Medical Ltd. generated $3.4M in revenue (+2.7% YoY), -$15.1M in net income, and -$14.6M in free cash flow against $13.9M in total assets and $13.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ICCM trading relative to its 50-day, 200-day, and 52-week technical levels?
ICCM last traded at $0.96 (-2.13% on volume of 56,714 shares), positioning the stock -42.17% below its 50-day simple moving average ($1.66) and -87.89% below its 200-day simple moving average ($7.93). Across its 52-week range of $0.82 to $23.49, ICCM sits at the 0.6% percentile with a 14-day RSI of 18.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.08).
ICCM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ICCM stock moving today?
Why ICCM Stock dropped -2.13% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.